PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN ...
Nov 1, 2005, 00:00
10.1016/S1098-3015(10)67250-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)67250-6/fulltext
Title :
PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER- COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN ...
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)67250-6&doi=10.1016/S1098-3015(10)67250-6
First page :
Section Title :
Open access? :
No
Section Order :
477